Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

25.34
-0.5600-2.16%
Post-market: 26.351.01+3.99%19:30 EDT
Volume:1.55M
Turnover:38.86M
Market Cap:3.03B
PE:-11.82
High:25.65
Open:25.65
Low:24.80
Close:25.90
52wk High:42.21
52wk Low:23.05
Shares:119.54M
Float Shares:92.51M
Volume Ratio:1.39
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1442
EPS(LYR):-1.7211
ROE:-36.81%
ROA:-20.11%
PB:4.80
PE(LYR):-14.72

Loading ...

NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026

Reuters
·
Aug 26

NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million

Reuters
·
Aug 26

NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms

Reuters
·
Aug 15

NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer

Reuters
·
Aug 15

Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Aug 08

NewAmsterdam Pharma Grants 28,000 Inducement Share Options at $27.79 to New Hires

Reuters
·
Aug 07

RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 06

Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Aug 06

NewAmsterdam Pharma Company N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe

Reuters
·
Aug 05

NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate

Benzinga Earnings
·
Aug 05

NewAmsterdam Pharma Q2 Net Loss Widens to USD 64.1 Million; Revenue Falls to USD 3.7 Million

Reuters
·
Aug 05

Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Dow Jones
·
Aug 05

Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval

Simply Wall St.
·
Aug 03

NewAmsterdam Pharma to Host Investor Day Webcast for Analysts, Investors

Reuters
·
Jul 29

Truist Financial Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Jul 27

Newamsterdam Pharma Says EU CHMP Backs Approval of Ubeslo, Evlarco Cholesterol Drugs

Reuters
·
Jul 27

Newamsterdam Says EU CHMP Backs Ubeslo, Evlarco Cholesterol Drugs for Approval

Reuters
·
Jul 26

Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Zevra Therapeutics (ZVRA)

TIPRANKS
·
Jul 25

Newamsterdam Pharma Says EMA Panel Backs EU Approval for Ubeslo, Evlarco Cholesterol Drugs

Reuters
·
Jul 24